



PPP 2026 Lead4Life Funding Information

KWF Kankerbestrijding

Oncode Institute

FAST

NRG Pallas

V1.0 May 5th, 2026

Content

Content.....	1
Goal of the program	2
Scope	2
Application process	4
Applications	4
Orientation Meeting	4
GMS	4
Health Innovation Netherlands (HI-NL) vouchers	4
Consortium	5
Statement sound position of the private partner	5
Timelines.....	6
Review Process.....	6
Eligibility check.....	6
Scientific Board Review	6
Patient Advisory Committee (PACO).....	7
Appeal.....	7
Monitoring.....	7
Financial Monitoring.....	8
Scientific Monitoring	8
Health~Holland Monitoring Criteria	8
Documents and templates.....	8
General conditions and eligibility criteria	9
Contact.....	9

Goal of the program

Lead4Life is a newly established Health~Holland public-private partnership (PPP) program in which KWF, FAST, NRG PALLAS and Oncode Institute combine their strengths. The program focuses on making the promising medical isotope lead-212 available at GMP quality, while simultaneously developing the technologies needed to enable its use in new radiopharmaceuticals and, ultimately, in cancer care.

Cancer remains one of the leading causes of death worldwide, and for many patients current treatment options are still limited. Radiopharmaceutical therapies already show clear benefits for certain cancers (e.g. Neuro-endocrine tumors or metastasized prostate cancer). Lead-212 is an alpha-emitting isotope with high energy delivered over a very short distance, offering the potential for more effective and precise cancer treatments. However, global availability of lead-212 is extremely limited, which slows down research, innovation, and access for patients.

At the same time, the growing international market for radiopharmaceuticals offers significant economic opportunities for countries with strong nuclear and medical infrastructure. By strengthening production capacity, enabling technologies and collaboration across the value chain, Lead4Life contributes not only to improved patient care but also to innovation, economic development and strengthening the Netherlands' international competitive position in the radiopharmaceutical field.

Scope

KWF invites public-private partnership (PPP) proposals that contribute to the aim of the Lead4Life program: the development of a reliable and scalable production technology for the non-exclusive supply of lead-212 and the enabling technologies required for its clinical application.

Proposals must clearly and directly contribute to strengthening the availability, scalability and/or clinical applicability of lead-212.

Projects may focus on one of the following pillars:

1. Lead production and supply chain

Projects should contribute to strengthening the reliability, scalability and accessibility of lead-212 (Pb-212) supply.

Examples of relevant topics include, but are not limited to:

- Production processes for Ra-224 and Th-228 as starting materials for Pb-212 generators;
- Development of Pb-212 generators.

2. Enabling technologies for clinical introduction of lead-212

Projects should contribute to enabling the safe and effective clinical application of lead-212-based radiopharmaceuticals.

Examples of relevant topics include, but are not limited to:

- Next generation chelators for Pb-212 (radio-)bioconjugates;
- Radiobiology;
- Imaging, dosimetry & pharmacokinetic modeling for Pb-212
- Quality control, analytical methods & safety framework for Pb-212
- Distribution network and ecosystem for Pb-212 Generators;
- Hospital infrastructure, radiation Protection & waste management

Furthermore, each application must meet at least the following criteria:

- The research aligns with the Knowledge and Innovation Agenda (KIA) 2024-2027 of the Top Sector LSH.
- The consortium consists of at least one for-profit enterprise and one research organization.
- The main applicant is a Dutch organization based in the Netherlands.
- The project is aimed at applied research with a focus on industrial research and/or experimental development. Elements of fundamental research may be eligible if properly justified.
- Projects at TRL 8 and 9, as well as phase-III clinical studies, are not permitted.
- The project is carried out at the joint expense and risk of all consortium partners, and all consortium partners contribute substantively to the project.
- The project has a maximum duration of four years and must start within six months of approval.

Application process

Applications

All project applications must use the mandatory PPP-2026-Lead4Life Project Application Form and the TKI-LSH Budget Form. In addition, applicants are required to complete all mandatory fields in the KWF Grant Management System (GMS), *with the exception of the “Budget” tab*. For the project budget, the TKI-LSH Budget Form takes precedence and serves as the leading document.

Applications that do not comply with these requirements will not be taken into consideration.

Templates for the required supporting documents are available under the section “Documents and Templates.”

Orientation Meeting

All applicants are encouraged to contact the programme group via KWF, FAST, NRG PALLAS, and/or Oncode Institute—to arrange an orientation meeting. You may reach out to the programme group at your discretion to initiate this process.

For matchmaking support, FAST can be contacted.

GMS

All applications have to be created and submitted via the KWF Grant Management System (GMS).

For contact and (technical) support regarding submissions through GMS, please contact KWF Team Besteding at kwf.nl/vraag.

Health Innovation Netherlands (HI-NL) vouchers

Project applications may be eligible for an "innovation guide" through [Health Innovation Netherlands \(HI-NL\)](#) under certain conditions. This advisory report provides insight into the steps needed for further development. The innovation guide can be funded with the PPP subsidy. This must be indicated in the application and included as an expense item in the budget. Please note HI-NL does not cover all areas of Life Sciences & Health.

This information is also included in the application form.

Consortium

All applications must be submitted by a consortium comprising at least one Dutch knowledge institute/research organization and one for-profit enterprise. The consortium should represent a genuine and well-aligned collaboration between the participating partners.

To ensure clarity and commitment, all agreements between partners must be formalized in a Consortium Agreement (CA), which must cover at minimum the entire duration of the project. A template of the compulsory model Consortium Agreement is available. All Consortium Agreements have to be approved by the Lead4Life programme group within 3 months after receipt of the grant offering letter. **If applicable: please indicate where changes to the template have been made.** Foreign for-profit enterprises and research organizations are encouraged to participate in the consortium as long as the results of the research project benefit the Dutch knowledge infrastructure and economy. The main applicant must be located in the Netherlands. The designated project leader is required to hold a formal appointment with the main applicant. The consortium is also asked to prevent (personal) conflicts of interests (COI) (see Appendix C of the “Appendices to the project application form”) between the public and the private partner.

Statement sound position of the private partner

It is mandatory for the grant recipients to declare that the private party is not an undertaking/company in difficulty. We ask all projects to sign the “[Verklaring geen onderneming in moeilijkheden](#)” declaration by the [Rijksdienst voor Ondernemend Nederland \(RVO\)](#) and upload this document with the application under “Letters of Commitment”

Timelines

Call opens:	May 5 th , 2026
Call closes:	September 22 th , 2026
Review process:	September 2026 – January 2027
Funding decision:	February 2027
Project start:	July 2027 at the latest

Review Process

Review of the projects before a grant offering decision follows the standardized KWF review process. For more information, visit [KWF review process](#). Within this call specifically, no pre-proposal or interviews are required.

Eligibility check

All submitted projects will undergo a procedural eligibility check by the Lead4Life programme group following submission and prior to evaluation by the Scientific Board. This check includes, but is not limited to, the following criteria:

- **Scope:** Does the project fall within the scope of the Lead4Life programme?
- **Eligibility of Participants:**
 - Is the lead institute eligible as lead for funding?
 - Are all consortium partners eligible for funding?
- **Budget Compliance:**
 - Is the proposed budget (and budget sheet) accurate and complete?
 - Have the applicants met the required minimum financial contribution?
- **Documentation Requirements:**
 - Are all mandatory documents included in the submission?
 - Does the project proposal comply with the maximum page limit of 15 pages?

Scientific Board Review

All projects will undergo evaluation by a dedicated PPP Scientific Review Board, composed of experts with a balanced mix of scientific knowledge and business development/valorization expertise. The Lead4Life programme group will publish the composition of the PPP Lead4Life Board in due course. The Board will be supported by advisory input from KWF, FAST, NRG PALLAS and Oncode Institute, and external review reports.

Each project will be independently assessed by a minimum of three Board Members. The evaluation will be based on specific criteria, including:

- **Scientific Quality**
- **Relevance and Impact**
- **Feasibility**

Each Board Member will assign scores per criterion, followed by an overall **Final Score**. After the individual evaluations, the Scientific Review Board will convene in a Board Meeting to finalize the scoring process. Projects will receive a final score on a scale from **1 to 5**, with scores above **3.0** considered **fundable**.

Following the Board Meeting, the Scientific Review Board and the Lead4Life programme group will hold a **Prioritization Meeting**. During this session, projects will be selected for funding based on their final ranking and available budget.

Patient Advisory Committee (PACO)

The programme group Lead4Life and Health~Holland highly value the (societal) input of patient representatives. As part of the review process, the **Patient Advisory Committee (PACO)—comprising (former) cancer patients—will evaluate the Dutch project summaries submitted.**

To support this, **project groups are required to submit a clear and complete Dutch summary in layman's terms via GMS.** This summary will be specifically reviewed by the PACO to ensure patient relevance and accessibility, and their input will be integrated into the overall assessment of the proposal. Representatives of the PACO will also attend the Scientific Board Meeting.

Appeal

All decisions made by Lead4Life may be appealed within two weeks after the official communication of the decision to the project leader, unless communicated otherwise. See: [KWF Reglement Bezwaar & Beroep \(in Dutch\)](#).

Monitoring

We aim to **invite all selected projects within the Lead4Life programme to participate in a voluntary symposium organized by the Lead4Life group**, prior to the official start of the projects.

The purpose of this event is to facilitate an informal meet-and-greet, and to provide an opportunity for project leaders, consortium members, and interested staff from KWF, FAST, NRG PALLAS and Oncode Institute to present and discuss their project plans.

While attendance is not mandatory, participation is strongly encouraged.

Financial Monitoring

Financial oversight will be carried out by a dedicated Public-Private Partnership (PPP) team within the KWF Grant management Department. This team ensures that all financial aspects of the project are tracked and aligned with programme requirements.

Scientific Monitoring

Each project will be assigned a science liaison, research manager and/or valorization expert from the Lead4Life programme group, who will be responsible for monitoring the scientific progress of the project. The (science) liaison will serve as the primary point of contact for the project group following the grant award. Details regarding the assigned science liaison and the associated monitoring responsibilities will be outlined in the grant offering letter and subsequent kick-off meeting.

Health~Holland Monitoring Criteria

In addition to LEAD4LIFE requirements, all project groups must also comply with the monitoring criteria established by Health~Holland. These requirements are described in the document titled ***“TKI-LSH PPS-2025-Lead4Life Funding Information, General Conditions and Eligibility Criteria”***, specifically under section 4.2.

Documents and templates

The following documents are available through the [KWF website](#):

- PPP 2025 Lead4Life Funding Information
- TKI-LSH PPP-2025-Lead4Life Funding Information, General Conditions and Eligibility Criteria - Dutch
- Template Consortium Agreement (Standard)
- Template Datamanagement Plan
- Template Letter of Commitment
- KWF-PPP Terms and Conditions 2026

The following documents can be downloaded through the [KWF Grant Management System](#) (after registration and starting a grant project proposal):

- PPS-2025-Lead4Life Project Application Form

- Appendices to the Project Application Form
- Contact Information Form to the Project Application Form
- References to the Project Application Form
- TKI-LSH (PPP) Budget Form

General conditions and eligibility criteria

All PPP applications must also meet the criteria and conditions for TKI-LSH PPP projects by Health~Holland. These can be found in the document “TKI-LSH PPS-2025-Lead4Life Funding Information, General Conditions and Eligibility Criteria” available on the [KWF website \(in Dutch\)](#). We strongly advise all project applicants to read this document in full.

Contact

KWF: pps@kwf.nl (PPP- and Call related questions)

FAST: info@FAST.nl (Matchmaking questions)

Oncode Institute: valorization@oncodeinstitute.nl (Valorisation questions)

For contact and (technical) support regarding submissions through GMS, please contact KWF Team Grant Management at kwf.nl/vraag.